INTERNATIONAL PATENT: ASTELLAS PHARMA INC. FILES APPLICATION FOR "COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2"

GENEVA, June 17 -- ASTELLAS PHARMA INC. (5-1, Nihonbashi-Honcho2-chome, Chuo-kuTokyo, 103-8411) filed a patent application (PCT/JP2023/044949) for "COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2" on Dec 08, 2023. With publication no. WO/2025/120866, the details related to the patent application was published on Jun 12, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): TANAKA, Hiroaki (c/o Astellas Pharma Inc.5-1, Nihonbashi-Honcho2-chome, Chuo-kuTokyo, 103-8411), NAKAZAWA, Taisuke (c/o Astellas Pha...